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Bleeding in carriers of hemophilia
Iris Plug, Eveline P. Mauser-Bunschoten, Annette H. J. T. Bröcker-Vriends, Hans Kristian Ploos van Amstel, Johanna G. van der Bom,
Joanna E. M. van Diemen-Homan, José Willemse, and Frits R. Rosendaal
A wide range of factor VIII and IX levels is
observed in heterozygous carriers of he-
mophilia as well as in noncarriers. In
female carriers, extreme lyonization may
lead to low clotting factor levels. We
studied the effect of heterozygous hemo-
philia carriership on the occurrence of
bleeding symptoms. A postal survey was
performed among most of the women
who were tested for carriership of hemo-
philia in the Netherlands before 2001. The
questionnaire included items on personal
characteristics, characteristics of hemo-
philia in the affected family members, and
carrier testing and history of bleeding
problems such as bleeding after tooth
extraction, bleeding after tonsillectomy,
and other operations. Information on clot-
ting factor levels was obtained from the
hospital charts. Logistic regression was
used to assess the relation of carrier
status and clotting factor levels with the
occurrence of hemorrhagic events. In
2004, 766 questionnaires were sent, and
546 women responded (80%). Of these,
274 were carriers of hemophilia A or B.
The median clotting factor level of carri-
ers was 0.60 IU/mL (range, 0.05-2.19 IU/
mL) compared with 1.02 IU/mL (range,
0.45-3.28 IU/mL) in noncarriers. Clotting
factor levels from 0.60 to 0.05 IU/mL were
increasingly associated with prolonged
bleeding from small wounds and pro-
longed bleeding after tooth extraction,
tonsillectomy, and operations. Carriers of
hemophilia bleed more than other women,
especially after medical interventions. Our
findings suggest that not only clotting
factor levels at the extreme of the distribu-
tion, resembling mild hemophilia, but also
mildly reduced clotting factor levels be-
tween 0.41 and 0.60 IU/mL are associated
with bleeding. (Blood. 2006;108:52-56)
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Introduction
Hemophilia is an X-linked hereditary bleeding disorder caused by a
deficient or defective coagulation factor VIII (hemophilia A) or
factor IX (hemophilia B). Resulting from the recessive X-chromo-
somal inheritance pattern, mostly men are affected while their female
relatives may be heterozygous for the mutation, often referred to as
carriers of hemophilia. Previously, pedigree analysis and clotting
factor VIII or IX levels were used to diagnose carriership for
hemophilia.1 In the early 1980s, it became possible to ascertain the
carrier status by means of DNA analysis, which has evolved from
haplotyping to mutation analysis offering certainty about the
carrier status.2 During the last 3 decades, genetic counseling,
carrier testing, and prenatal diagnosis of hemophilia have become
an integrated part of the comprehensive care for hemophilia.3
Female carriers are expected to have a plasma concentration of
factor VIII or IX corresponding to half the concentration found in
healthy individuals, which is generally sufficient for normal
hemostasis. However, in carriers a wide range in clotting factor
levels is seen, from very low, resembling affected males, to the
upper limit of normal.4 This range has been attributed to the
phenomenon of lyonization, random X-chromosome inactivation,
which takes place in the early embryonic life.5 Other genetic
factors, such as ABO blood group, may also affect factor VIII and
IX plasma concentrations in carriers as well as noncarriers, in
whom a wide distribution also is observed.6
Although Merskey and Macfarlane7 already reported excessive
bleeding after tooth extraction in 47% of known carriers (n  19)
in 1952, this first publication was not followed by larger studies.
Some case series showed joint bleeds, prolonged bleeding after
tonsillectomy, tooth extractions, or postpartum bleeding.8-13
It is important to assess the risk of bleeding in carriers of
hemophilia to enable physicians to improve care for hemophilia
carriers, for instance, by the implementation of prophylactic
intervention in carriers at risk for bleeding.
While extensive information on bleeding in men with hemo-
philia is available, only a few studies have focused on bleeding in
carriers. We present a large national cross-sectional study examin-
ing bleeding in women in whom genetic testing for hemophilia was
performed within the last decade. We focused on spontaneous
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bleeding events, bleeding after trauma, and bleeding following
surgical interventions.
The aim of this study was to examine the risk of bleeding among
carriers of hemophilia A or B compared with noncarriers.
Patients and methods
Subjects
We contacted all women who had been tested for carriership of hemophilia
A or B before 2001 in the Netherlands. The women had to be 18 years or
older to participate. Diagnosis of carriership of hemophilia was based on
DNA analysis, pedigree analysis, or the assessment of clotting factor levels.
Carriers of hemophilia were women in whom the genetic defect related to
hemophilia was established through DNA analysis (haplotype or mutation
analysis) or, before 1985, through the determination of clotting factor levels
in combination with pedigree analysis. Noncarriers were women in whom
testing showed that they were not likely to be carrying the mutation that
caused hemophilia A or B in their family, by the same procedures as for
carriers. By comparing carriers with noncarriers both from hemophilic families
we excluded the possible bias introduced by knowledge of hemophilia.
Assessments
Questionnaires were sent by mail, followed by 2 reminder letters. The
questionnaire included items on personal characteristics, type and severity
of hemophilia in affected relatives, carrier testing, and several bleeding
problems. We assessed whether patients ever reported spontaneous bleed-
ing and bleeding after trauma: bruising, nose bleeds, gum bleedings, and
joint bleeds. Questions on bleeding after medical interventions included
bleeding after tooth extractions, adenotomy or tonsillectomy, and opera-
tions. Prolonged bleeding after medical interventions was defined as
bleeding for more than 3 hours after tooth extractions, adenotomy or
tonsillectomy, or operations. The topics on bleeding were based on a
validated questionnaire developed by Šrámek et al, validated by means of
sensitivity analysis.14 Restrictions in daily life due to excessive blood loss
during the menstrual period were measured on a 7-point scale in which a
score of 1 represented no restrictions, and a score of 7, severe restrictions.
To evaluate the questionnaire a pilot study was performed in 12 carriers.
Informed consent was obtained to allow us to verify the diagnosis (type and
severity of hemophilia in the family) and to obtain information on factor
VIII and IX activity from the medical files of the patients in the hemophilia
treatment centers. In most women, clotting factor activity had been
determined at several time points, in which case the lowest value was used
for evaluation in this study. Severity of hemophilia in the male family
members was classified according to residual percentage of factor VIII or
IX clotting activity: severe (less than 0.01 IU/mL), moderate (0.01 to 0.05
IU/mL), or mild (more than 0.05 to 0.40 IU/mL). The Committee of
Medical Ethics of the Leiden University Medical Center approved
this study.
Data analysis
Women with clotting disorders due to other causes than hemophilia or who
used antithrombotic medication were excluded from the analysis. The
prevalence of bleeding symptoms in women who were carriers of hemo-
philia A or B was compared with that of women not carrying a hemophilia
mutation. Due to the limited number of women reporting hemophilia B in
the family, we could not distinguish between the 2 types of hemophilia in
the analysis. The risk of bleeding related to the carrier status and clotting
factor levels was determined, and we tested for a graded response using a
Wald test. If in the comparison between carriers and noncarriers a specific
bleeding event showed a relative risk (RR) above 1 and a 95% confidence
interval (CI) not including 1, its association with clotting factor levels is
also presented. In the analysis of bleeding risk caused by specific
interventions, only women who ever underwent this intervention were
included in the analysis. Women who were treated with tranexamic acid,
desmopressin, or clotting factor preparations before the medical interven-
tion were excluded from the analysis because this affects the preexisting
bleeding risk. Clotting factor levels were analyzed as a categorical variable;
the studied categories were as follows: 0.40 IU/mL or below, 0.41 to 0.60
IU/mL, and more than 0.60 IU/mL. In the analysis of excessive blood loss
during the menstrual period, only women who were premenopausal were
included. To exclude the effect of referral for carrier testing because of
bleeding problems, we calculated the risk of bleeding after adenotomy or
tonsillectomy or operations among women who were not tested because of
an increased bleeding tendency.
Results
Response and patient characteristics
A total of 766 questionnaires were sent, and 546 questionnaires
were completed and returned (response of 80%). Excluded from
analyses were women who reported clotting disorders other than
hemophilia (19 women of whom 13 had von Willebrand disease)
and 10 women in whom the carrier status was not conclusive or
unknown. This resulted in 274 carriers and 245 noncarriers for the
current analyses. Table 1 shows the general characteristics accord-
ing to hemophilia carrier status. The median age of the carriers and
noncarriers was similar: 39 years (range, 18-77 years) and 40 years
(range, 20-90 years), respectively. Current use of oral contracep-
tives in carriers and noncarriers was similar, at 29% and 27%,
respectively. Past use of oral contraceptives was reported by 159
carriers (51%) and by 119 noncarriers (56%). Carrier testing by
means of DNA analysis, available in the Netherlands since 1985,
was performed in 177 carriers (57%) and in 122 noncarriers (58%).
Factor VIII and IX characteristics
Clotting factor levels were missing for 18% (49 of 274) of carriers
and 43% (103 of 245) of noncarriers. The median clotting factor
level in carriers was 0.60 IU/mL (range, 0.05-2.19 IU/mL)
compared with 1.02 IU/mL (range, 0.45-3.28 IU/mL) in noncarri-
ers. Sixty-two carriers and none of the noncarriers had a clotting
factor level of 0.40 IU/mL or below. Figure 1 shows the distribution
of clotting factor levels in carriers and noncarriers.
Bleeding symptoms
Spontaneous bleeding and bleeding after trauma. Table 2
presents the risk of (ever having experienced) bleeding of carriers
compared with noncarriers. The risk of prolonged bleeding (more
than 5 minutes) from small wounds was 2 times higher (RR, 2.2;
95% CI, 1.4 to 3.5) in carriers than noncarriers.
Table 1. General characteristics of study population
Carrier of hemophilia
Yes No
No. patients 274 245
Mean age at questionnaire, y (range) 39 (18-77) 40 (20-90)
Current use of oral contraceptives, no. (%) 79 (29) 65 (27)
Family, no. (%)
Severe hemophilia in family* 140 (51) 113 (46)
Hemophilia A in family† 230 (84) 151 (62)
Clotting factor
Clotting factor levels available, no. (%) 225 (82) 143 (58)
Median factor VIII:C, IU/mL (range) 0.60 (0.05-2.19) 1.02 (0.45-3.28)
*As opposed to moderate and mild hemophilia; 73 women reported they did not
remember the severity of hemophilia in their male family members.
†As opposed to hemophilia B; 95 women reported they did not remember the
type of hemophilia in their family.
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Low clotting factor levels were associated with an increased
occurrence of prolonged bleeding from small wounds and joint
bleeding (Table 3). Joint bleeds were reported by 8% of carriers and
by 5% of women not carrying hemophilia, which was a 2 times
increased risk (RR, 1.9; CI, 0.9 to 3.7). Although no higher risk of
nose bleeds was observed in carriers compared with noncarriers,
prolonged nose bleeding occurred more often in carriers: 9% of
carriers had nose bleeds that lasted longer than 10 minutes
compared with 2% of noncarriers. Seventeen percent of carriers
had received treatment for nose bleeds compared with 10% of
noncarriers. Carriers of hemophilia did not have a higher risk of
large bruising and gum bleeding.
Bleeding after medical interventions. Tooth extractions had
been performed in 228 carriers and 219 noncarriers, and the risk of
bleeding for more than 3 hours after tooth extraction was 2 times
higher in carriers than noncarriers (RR, 2.3; CI, 1.5 to 3.4) (Table
4). In 24 of 228 carriers, additional treatment due to bleeding after
tooth extractions had been required compared with 1 of 219
noncarriers. Treatment included intervention by a dentist or the use
of tranexamic acid, desmopressin, or administration of clotting
factor concentrate. Clotting factor levels below 0.60 IU/mL were
associated with prolonged bleeding after tooth extraction. A total of
123 carriers and 122 noncarriers underwent tonsillectomy or
adenotomy; 24% of carriers and 13% of noncarriers reported
bleeding for more than 3 hours following tonsillectomy (RR, 1.8;
CI, 1.0 to 3.1). In 8 carriers (3%), a blood transfusion was required
after (adeno) tonsillectomy compared with none of the noncarriers.
Eight percent of women carrying hemophilia needed treatment for
bleeding following surgery. In most cases, a second intervention to
treat bleeding had to be performed. Decreasing clotting factor
levels were also associated with prolonged bleeding after (adeno)
tonsillectomy. Women with a clotting factor level of 0.40 IU/mL or
below had a 2.1 times (RR, 2.1; CI, 1.1 to 3.9) increased risk
compared with women with a clotting factor level above 0.60
IU/mL. Prolonged bleeding for more than 3 hours after 1 or more
operations was reported by 46 of 163 carriers and by 16 of 146
noncarriers (RR, 2.6; CI, 1.5 to 4.3). Women with a clotting factor
level of 0.40 IU/mL or below had a 3 times (RR, 3.2; CI, 1.8 to 5.7)
increased risk of prolonged bleeding after operations compared
with women with a clotting factor level of 0.60 IU/mL and above.
Additional treatment during or after surgery due to bleeding
problems was necessary in 6% (21 of 370) of the operations
performed in carriers and in 2% (6 of 328) of the noncarriers. One
or more blood transfusions were required in 11% of operations in
participants carrying hemophilia compared with 7% in noncarriers.
Other additional treatment consisted of infusion of clotting factor
concentrate or a second operation.
Table 2. Spontaneous bleeding or bleeding after trauma in carriers





event/total (%) RR (CI)
Nose bleeds ever
reported 115/270 (43) 105/237 (44) 1.0 (0.8-1.2)
Bruising 50/269 (19) 42/243 (17) 1.1 (0.7-1.6)
Small wounds 56/262 (21) 23/237 (9) 2.2 (1.4-3.5)
Gum bleeding present 164/271 (60) 148/243 (61) 1.0 (0.9-1.1)
Joint bleeds 23/271 (8) 11/240 (5) 1.9 (0.9-3.7)
Figure 1. Clotting factor level in relation to carrier status shown for participants
for whom clotting factor level is known. This box-whisker plot shows the median
and the interquartile range of clotting factor activity levels in carriers and noncarriers.
The box is marked by the first and the third quartile; the whiskers indicate the range.
The stacked asterisks indicate two extremes (2.09 and 2.19 IU/mL).
Table 3. Bleeding tendency of both carriers and noncarriers









Small wounds  .01
Event/total (%) 28/233 (12) 25/64 (39) 11/60 (18)
RR (CI) 1 3.3 (2.0-5.2) 1.5 (0.8-2.9)
Joint bleeds .06
Event/total (%) 12/241 (5) 9/65 (14) 6/62 (10)
RR (CI) 1 2.8 (1.2-6.3) 1.9 (0.8-4.9)
Tonsillectomy .06
Event/total (%) 21/124 (17) 6/26 (23) 11/31 (35)
RR (CI) 1 1.4 (0.6-3.0) 2.1 (1.1-3.9)
Tooth extraction  .01
Event/total (%) 18/139 (13) 14/51 (27) 15/36 (42)
RR (CI) 1 1.8 (1.0-3.0) 2.5 (1.5-4.2)
Operations  .01
Event/total (%) 18/139 (13) 14/49 (29) 15/36 (42)
RR (CI) 1 2.2 (1.2-4.1) 3.2 (1.8-5.7)
Bleeding score 2 or
above, RR (CI) 1 3.0 (1.5-5.8) 4.0 (2.1-7.7)  .01
Women who ever received treatment with clotting factor concentration, tranex-
amic acid, or desmopressin before tooth extraction, tonsillectomy, or operations were
excluded from the analysis.




event/total (%) RR (CI)
Tooth extraction
Prolonged bleeding;
more than 3 h 61/228 (27) 26/219 (12) 2.3 (1.5-3.4)
Treatment after




more than 3 h 29/123 (24) 16/122 (13) 1.8 (1.0-3.1)
Treatment after
intervention 10/123 (8) 1/122 (0.8) 9.9 (1.3-76.3)
Operations
Prolonged bleeding;
more than 3 h 46/163 (28) 16/146 (11) 2.6 (1.5-4.3)
Treatment; ever 16/174 (9) 6/149 (4) 2.3 (0.9-5.7)
Blood transfusion 29/174 (17) 18/149 (12) 1.4 (0.8-2.4)
Participants who had been treated prior to the clinical intervention with clotting
factor preparations, tranexamic acid, or desmopressin were excluded from the
analysis.
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After the exclusion of women in whom bleeding problems were
not the indication for carrier testing, the risks of prolonged bleeding
after operations (RR, 2.8; CI, 1.6 to 5.0) or tonsillectomy (RR, 1.8;
CI, 0.9 to 3.4) were similar to the finding in the whole study
population. Although obligatory carriers reported bleeding symp-
toms slightly more often than carriers who could not have been
aware of their status prior to testing, these differences did not
materially affect the estimates.
Excessive bleeding during menstrual period. Women with
lower clotting factor levels more often reported excessive blood
loss during the menstrual period (menorrhagia) (Table 5). Simi-
larly, the risk of requiring iron suppletion was 80% increased (RR,
1.8; CI, 0.7 to 5.0) in women with a clotting factor level of 0.40
IU/mL or below compared with women with a clotting factor level
of 0.60 IU/mL and above. Sixty-two (23%) women carrying
hemophilia visited the general practitioner for excessive bleeding
during the menstrual period compared with 20% (n  47) of
noncarriers. Fifty-eight women (31 carriers [11%] and 21 noncarri-
ers [9%]) consulted a gynecologist, and in 18 women a hysterec-
tomy was performed for this reason. Mild to severe restrictions in
daily life due to excessive blood loss during the menstrual period
were reported by 18% of women with a low clotting factor level
compared with 9% of the women with a clotting factor level above
0.60 IU/mL (RR, 2.3; CI, 1.0 to 5.6).
Discussion
Although hemophilia is a well-known bleeding disorder in men, it
is seldom recognized that female carriers of hemophilia might not
only have an increased bleeding tendency but that the symptoms
may be frequent and severe. We studied the risk of bleeding among
carriers of hemophilia A or B compared with that of noncarriers.
Although usually a level of 0.40 IU/mL is used as the upper limit
defining hemophilia, we found an increased risk of bleeding in
women with clotting factor levels between 0.41 and 0.60 IU/mL.
Carriers of hemophilia experience more spontaneous and provoked
hemorrhages than noncarriers, with a higher risk of prolonged
bleeding after operations, tooth extractions, and tonsillectomy. The
risk is highest in those with the lowest clotting factor levels.
In this study, we approached all women who had been
counseled and tested for carriership of hemophilia A or B in the
Netherlands. Eighty percent of women responded to the question-
naire. We included 519 women, which makes this currently the
largest survey into the hemorrhagic risk in female relatives of men
with hemophilia. Nonresponders were somewhat older than the
responders. Yet, age did not modify the association between the
clotting factor levels and the risk of bleeding. We therefore assume
our results to be generalizable to carriers of hemophilia in general.
Recall bias may have influenced the reporting of bleeding symp-
toms, because questions were asked after carrier testing. Yet,
Mauser-Bunschoten et al showed by comparing bleeding tendency
in obligatory carriers with normal factor VIII levels to noncarriers
that the awareness of carrier status has little influence on the
reported frequency of bleeding.10 A more serious problem is that
women who grew up in families with hemophilia patients may
judge bleeding symptoms differently from women in the general
population. Selection bias may have been introduced if carrier
testing was done because of bleeding problems. To counter this
problem as well as the possible incomparability of carriers from
hemophilia families to women from the general population, we
only included women from families known to be affected by
hemophilia. The carriers and noncarriers in our study had grown up
in the same environment and had not been aware of their carrier
status until testing. Therefore, even if carrier testing was done because of
bleeding symptoms, which was the case in 7% of participants, this
would not have affected the comparison. In some hemophilia centers, it
is routine to measure clotting factor levels in all obligatory carriers.
However, despite careful counseling not all carriers are aware of
their clotting factor level. Clotting factor levels were missing for
18% of carriers and 43% of noncarriers. Although the group of
women in whom clotting factor levels had been measured is most likely
to be different from the group in whom these are missing, this will not
affect the observed relation between clotting factor levels and bleeding.
Because this is a self-reported questionnaire, bleeding symp-
toms might have been overreported as well as underreported. In
some cases, oozing might have been reported as bleeding. On the
other hand, in families where blood loss is a well-known and
accepted phenomenon, abnormal bleeding might not have been
recognized as such.
Finally, information on the lowest clotting factor activity ever
measured was collected from the medical files. We did not have
insight into the reasons for these assessments. It is well known that
clotting factor levels may vary considerably according to various
circumstances (eg, pregnancy and stress). Yet, most investigations
were done outside specific risk circumstances. We believe, there-
fore, that the additional variation in the levels will have had limited
effect, although it may have caused an overestimation of risk
among the higher clotting factor level categories.
In the literature, mild hemophilia is defined as a clotting factor
level of below 0.40 IU/mL. This cutoff point is also described in the
guidelines set by the subcommittee of the International Society on
Thrombosis and Haemostasis15 (ISTH) and is used in clinical
practice. Our study shows that the risk of bleeding is increased in
women who would be defined as having mild hemophilia but also
in women with clotting factor levels between 0.41 and 0.60 IU/mL.
These findings could have implications for the currently used
definition of clotting factor levels considered to be “reliable” to
perform medical interventions.
We found a moderately increased risk of joint bleedings in
carriers. We have no explanation for this; possibly joint bleeds were
overreported due to confusion with superficial bleeding of tissue in
Table 5. Characteristics of the menstrual period reported by both










Excessive blood loss .07
Frequency, no. (%) 93/195 (48) 31/54 (57) 31/51 (61)
RR (CI) 1 1.2 (0.9-1.6) 1.3 (1.0-1.7)
Anemia .07
Frequency, no. (%) 16/195 (8) 9/54 (17) 8/51 (16)
RR (CI) 1 2.0 (1.0-4.3) 1.9 (0.9-4.2)
Iron suppletion .07
Frequency, no. (%) 15/195 (8) 11/54 (20) 7/51 (14)
RR (CI) 1 2.6 (1.3-5.4) 1.8 (0.8-4.1)
Hysterectomy* .9
Frequency, no. (%) 7/44 (16) 2/10 (20) 2/11 (18)
RR (CI) 1 1.3 (0.3-5.2) 1.1 (0.3-4.8)
Restrictions in daily life† .04
Frequency, no. (%) 17/189 (9.0) 9/53 (17) 9/49 (18)
RR (CI) 1 2.0 (0.8-4.9) 2.3 (1.0-5.6)
*Reported by postmenopausal women due to excessive blood loss.
†Moderate to severe restrictions in daily life due to excessive blood loss during
the menstrual period.
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the joint region. It seems unlikely from clinical practice that this is
the true estimate of joint bleeds in carriers.
Our study mainly shows an increased risk of bleeding after
trauma and medical interventions, which is similar to the clinical
profile of mild hemophilia and in line with a previous study in
carriers.10 Our findings underline the importance for clinicians and
carriers to be aware of the complications that may occur after
operations in carriers of hemophilia. Both the clinician and the
carrier should be informed of the clotting factor level, which is
strongly related to the hemorrhagic risk.
However, in many carriers the clotting factor levels were either
not measured or not known to the woman. It is clear that not only in
obligatory carriers, such as daughters of hemophilia patients, but
also in potential carriers, clotting factor levels should be measured
preceding a medical intervention, also at a young age. The clotting
factor levels in carriers are independent of severity of hemophilia
within the family and vary from person to person.16 This indicates
the importance of clotting factor measurement during carrier
testing in all women related to men with hemophilia, independent
of the severity of hemophilia and family history unless carrier
status is excluded by DNA analysis.
In conclusion, our study suggests a higher risk of bleeding in
carriers of hemophilia related to clotting factor levels, especially
after medical interventions. This emphasizes the importance of the
measurement of clotting factor levels before interventions in all
carriers and potential carriers of hemophilia.
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